$33.00
Manufacturer: Hungary
Medications used in dementia. Cholinesterase inhibitors. ATX code N06D A02.
Adult and elderly patients.
Treatment begins with a dose of 5 mg / day (taken once a day). Alzepil should be taken orally in the evening, just before bedtime. Doses of 5 mg/day should be followed for at least one month to ensure the earliest possible clinical response to treatment as assessed and to achieve steady-state concentrations of donepezil. After clinical evaluation of treatment at a dose of 5 mg / day for 1 month, the dose of donepezil can be increased to 10 mg / day (taken once a day).
The maximum recommended daily dose is 10 mg. Doses greater than 10 mg/day have not been studied in clinical studies.
Description
Ingredinets
active ingredient: donepezil;
1 film-coated tablet contains donepezil 5 mg;
excipients: microcrystalline cellulose, low-substituted hydroxypropyl cellulose, magnesium stearate, hypromellose, titanium dioxide (E 171), macrogol 400.
Pharmacotherapeutic group
Medications used in dementia. Cholinesterase inhibitors. ATX code N06D A02.
Pharmacodynamics
Selective and reversible inhibitor of acetylcholinesterase, which is the main type of cholinesterase in the brain. By inhibiting cholinesterase in the brain, donepezil blocks the breakdown of acetylcholine, which transmits nerve excitation to the central nervous system. Donepezil inhibits acetylcholinesterase more than 1000 times more potent than butyrylcholinesterase found in structures located primarily outside the central nervous system.
After a single dose of donepezil in doses of 5 mg or 10 mg, the degree of inhibition of acetylcholinesterase activity is estimated in erythrocyte membranes and is 63.6% and 77.3%, respectively.
Inhibition of acetylcholinesterase in erythrocytes by donepezil correlates with changes in the ADAS-cog scale (Cognitive Assessment Scale for Alzheimer’s Disease).
Indications
Symptomatic treatment of mild to moderate Alzheimer’s disease.
Contraindications
Hypersensitivity to donepezil, piperidine derivatives or any of the excipients of the drug.
Directions
Adult and elderly patients.
Treatment begins with a dose of 5 mg / day (taken once a day). Alzepil should be taken orally in the evening, just before bedtime. Doses of 5 mg/day should be followed for at least one month to ensure the earliest possible clinical response to treatment as assessed and to achieve steady-state concentrations of donepezil. After clinical evaluation of treatment at a dose of 5 mg / day for 1 month, the dose of donepezil can be increased to 10 mg / day (taken once a day).
The maximum recommended daily dose is 10 mg. Doses greater than 10 mg/day have not been studied in clinical studies.
Treatment should be initiated and continued under the supervision of a physician experienced in diagnosing and treating Alzheimer’s dementia. The disease must be diagnosed in accordance with generally accepted recommendations (for example,
DSM IV or ICD 10 – International Classification of Diseases, 10th edition).
Therapy with donepezil should only be started if a caregiver is available to continuously monitor the patient’s pill intake.
Maintenance treatment may be continued as long as the patient is receiving therapeutic benefit. Therefore, the clinical benefit of donepezil litter should be regularly assessed. If evidence of a therapeutic effect is no longer observed, consideration should be given to discontinuing the drug. Individual response to donepezil cannot be predicted.
With the abolition of treatment, a gradual decrease in the beneficial effect of donepezil is observed.
Impaired kidney and liver function
For patients with impaired renal function, the same dosing regimen can be followed, since the clearance of donepezil will not change in this condition.
Due to the possible increase in exposure in mild or moderate hepatic insufficiency, dose increases should be carried out depending on the individual tolerability of the drug. No data are available for patients with severe hepatic impairment.
Recent Reviews